Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Insulet Corporation
The major players in the diabetes tech sector announced new and re-hashed old clinical data at this year’s American Diabetes Association Scientific Sessions in New Orleans.
Dexcom may be planning to purchase Insulet to enter the insulin pump market and transform itself into a diabetes tech giant.
Senseonics announced the long-awaited FDA approval of its Eversense E3 implantable CGM, featuring a sensor that lasts up to six months. The company is also developing a one-year version of Eversense and a transmitter-less version, but the stock market is disappointed with its sales projections.
Omnipod 5 is the first tubeless automated insulin delivery system compatible with Dexcom’s G6 continuous glucose monitoring system to automatically adjust insulin levels.
- Medical Devices
- Other Names / Subsidiaries
- Insulet Canada Corporation
- Neighborhood Diabetes
- Neighborhood Holdings, Inc.